ASND

COPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being held in Toronto, Canada, from August 26-29, 2026, will include an oral presentation of Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. The presentation will be given by Carlos Bacino, M.D., FACMG, Professor of Molecular and Human Genetics, Baylor College of Medicine and Texas Children’s Hospital. "This long-term data reinforces the benefits seen in clinical trials of once-weekly TransCon CNP, which hav

BMO Capital Markets initiated coverage of Ascendis Pharma with a rating of Outperform and set a new price target of $319.00

4 - Ascendis Pharma A/S (0001612042) (Issuer)

First patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection Milestone marks Eyconis’ transition to a clinical-stage biotechnology company REDWOOD CITY, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Eyconis, Inc., a biotechnology company developing next-generation, long-acting ophthalmic therapeutics, today announced the initiation of OVERTURE, the company’s first-in-human Phase 1b/2a clinical trial of EYC-0305 in treatment-naïve patients with neovascular, or wet, age-related macular degeneration (AMD). The first patients have been dosed in the study,

SCHEDULE 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

6-K - Ascendis Pharma A/S (0001612042) (Filer)

6-K - Ascendis Pharma A/S (0001612042) (Filer)

– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH®, €55 million for SKYTROFA®, and €8 million for YUVIWEL® – Through July 31, more than 220 unique YUVIWEL patient enrollments in the U.S. – Substantial pipeline updates: presented long-term Phase 2 & 3 YORVIPATH data, shared Week 78 COACH Trial data, and completed target enrollment for pivotal infant reACHin Trial – Settled all convertible notes and Ascendis added to multiple Russell U.S. Indexes – Conference call today at 8:00 am ET COPENHAGEN, Denmark, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the second quarter ended J

6-K - Ascendis Pharma A/S (0001612042) (Filer)

COPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on August 13, 2026, at 8:00 a.m. Eastern Time (ET) to discuss its second quarter 2026 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://inves

6-K - Ascendis Pharma A/S (0001612042) (Filer)

TransCon® CNP and TransCon hGH combination therapy Week 78 data from the Phase 2 COACH Trial showed durable, unprecedented increase in healthy, proportional growthTransCon CNP monotherapy Week 104 data from the pivotal ApproaCH Trial demonstrated durable improvements in height, body proportionality, and lower-limb alignmentCompleted target enrollment for pivotal reACHin Trial supporting planned regulatory filings for infants 0 to <2 years of age with achondroplasiaSafety and tolerability of monotherapy and combination therapy remained consistent with previously reported dataMore than 170 unique YUVIWEL patient enrollments in the U.S., with more than 65% approved for reimbursement, through Ju

6-K - Ascendis Pharma A/S (0001612042) (Filer)

6-K - Ascendis Pharma A/S (0001612042) (Filer)

Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104Greater improvements observed in children with preexisting genu varum (leg bowing) COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA)

6-K - Ascendis Pharma A/S (0001612042) (Filer)

COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026. The Russell 3000® Index tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. Within the Russell 3000®, the Russell 1000® Index comprises the 1,000 largest securities, representing more than 90% of investable

COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th International Conference on Children's Bone Health being held in Montreal from June 27-30. The data include an oral presentation of Week 104 data showing improvements in lower-extremity alignment from the recently completed pivotal ApproaCH Trial of TransCon® CNP (navepegritide) by Leanne Ward, M.D., Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa (Canada), as well as a

6-K - Ascendis Pharma A/S (0001612042) (Filer)

6-K - Ascendis Pharma A/S (0001612042) (Filer)

Multi-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark, June 13, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced Week 182 data from its completed Phase 3 PaTHway Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the three-and-a-half-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems –

6-K - Ascendis Pharma A/S (0001612042) (Filer)

– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN, Denmark, June 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced 5-year (Week 266) data from its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) demonstrated sustained efficacy and safety in adults with hypoparathyroidism. Over the five-year duration of the trial, TransCon PTH replicated the systemic actions of endogenous PTH, with a balanced, beneficial impact on the main target organ systems – kidney

6-K - Ascendis Pharma A/S (0001612042) (Filer)

COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency will be shared in two oral presentations and three posters at ENDO 2026, the annual meeting of the Endocrine Society being held in Chicago from June 13-16, 2026. "As a leader in rare endocrine diseases, we are committed to sharing comprehensive clinical trial results in peer-reviewed forums that reinforce the transformative potential of our innovative therapies," said Aimee Shu, M.D., Executive Vice President, Chief Medical Officer at Ascendis